Short-term efficacy and influencing factors of conventional chemotherapy combined with irinotecan in patients with advanced gastric cancer

Table 5 Comparison of SF-36 scale scores before and after treatment in two groups

Index	Observation group (n = 40)	Control group (n = 40)	t value	P value
Physiological function
Before treatment	52.34 ± 6.89	54.11 ± 7.04	-1.136	0.259
3 mo after treatment	65.12 ± 8.14a	60.32 ± 8.04a	2.653	0.010
Role-physical
Before treatment	60.43 ± 7.92	59.90 ± 8.04	0.297	0.767
3 mo after treatment	64.54 ± 8.09a	63.93 ± 7.90a	0.341	0.734
Bodily pain
Before treatment	31.88 ± 7.78	32.01 ± 8.09	-0.073	0.942
3 mo after treatment	38.00 ± 8.12a	38.70 ± 9.17a	-0.361	0.719
General health
Before treatment	58.56 ± 9.15	57.74 ± 9.03	0.403	0.688
3 mo after treatment	66.43 ± 7.12a	65.80 ± 9.22a	0.342	0.733
Energy
Before treatment	40.32 ± 7.22	38.75 ± 8.11	0.914	0.363
3 mo after treatment	54.76 ± 6.70a	47.21 ± 7.14a	4.877	0.000
Social function
Before treatment	51.21 ± 6.98	51.33 ± 7.54	-0.074	0.941
3 mo after treatment	61.89 ± 6.45a	60.40 ± 7.16a	0.978	0.331
Emotional function
Before treatment	31.65 ± 7.21	31.44 ± 8.01	0.123	0.902
3 mo after treatment	47.58 ± 7.22a	39.03 ± 8.12a	4.977	0.000
Mental health
Before treatment	40.34 ± 6.31	39.45 ± 7.08	0.594	0.555
3 mo after treatment	66.16 ± 8.11a	50.91 ± 9.03a	7.947	0.000

^aP < 0.05 vs before treatment.